Tiziana Life Sciences
- Biotech or pharma, therapeutic R&D
Foralumab our lead asset is the only fully human, anti-CD3. Foralumab is delivered intranasally to patients who suffer from non-active secondary progressive multiple sclerosis and Alzheimer's.
Address
New YorkNew York
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}